-
A. Alfred Taubman had a lot to lose at his trial on price-fixing charges.
FORBES: The Taubman Trial
-
Lawyers for Alfred Taubman, the former Sotheby's chairman on trial for price fixing, blame Diana Brooks.
FORBES: The Taubman Trial
-
However, it said that only a small group of people are being test-marketed in what it describes as a 'price trial' for the card.
BBC: NEWS | Programmes | Moneybox | Double Mint offer exposed
-
So he held a trial to determine if Price and Coleman really were the love-birds Price claimed they were.
FORBES: Court Rules Against Gary Coleman's Ex, Finds She Abused And Cheated On Him
-
We know them because we can measure them with attributes more tangible than those found in an orgone collector, like product trial, purchase, price premium, and repeat sales.
FORBES: Bad Decisions And No Results: What You Can Learn From Super Bowl Advertisers' Mistakes
-
It is not possible to appeal to trial and error for establishing the right price because of the lags and the inefficiencies implied by the inevitable errors.
ECONOMIST: Carbon tax or trade?
-
They analyzed each closing stock price before and after the date of a public announcement and found that the average stock price 120 days before a phase III clinical trial announcement showed an increase of 13.7 percent for companies that reported positive trials and a 0.7 percent drop for those reporting negative trial results ( here is the abstract).
FORBES: Why Pharma Stocks May Rise Before Trial Data Is Released
-
If the trial shows that the stoves can be sold, even at a subsidized price, work on establishing a sustainable market can begin, providing access to the stove for many more women in Darfur and elsewhere than would ever be possible through donor grants alone.
FORBES: How A Market-Based Approach Can Solve A Humanitarian Problem In Darfur
-
Sean Price argued that publicity about the outcome could prejudice jurors in the event of a trial following the outcome of Operation Sacristy.
BBC: Sean Price misconduct hearing delay bid fails
-
Pfizer's share price plunged after higher-than-expected mortality and side effects reported during a clinical trial led it to scrap a drug it had been developing since 1992.
ECONOMIST: Business this week
-
The trial bar's strategy against corporate America up to now has been to file a suit, depress the stock price and bring the company to the table to get a settlement out of it, he said.
FORBES: Magazine Article